Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Dahkki Amr El Zawily (14851115)

Fáttát:

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma Dahkki Yuncheng Bei (16546095)

Fáttát:

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma Dahkki Yuncheng Bei (16546095)

Fáttát:

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma Dahkki Yuncheng Bei (16546095)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer Dahkki Xu Hua (14954032)

Fáttát:

Supplementary Table 2 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer Dahkki Qin-Shu Li (16990832)

Fáttát:

Supplementary Table 1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer Dahkki Qin-Shu Li (16990832)

Fáttát: